Therapeutic compounds

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8455477
APP PUB NO 20110207711A1
SERIAL NO

13057325

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MSD K KCHIYODA-KU TOKYO 102-8667

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hou, Yongquan Cambridge, US 1 53
Ito, Satoru Tsukuba, JP 176 3339
Jewell, James Somerville, US 1 53
Jung, Joon Newton, US 35 172
Kattar, Solomon Arlington, US 16 197
Katz, Jason Newton Highlands, US 54 857
MacCoss, Rachel Brookline, US 1 53

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 4, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00